Generated by AI
NextCure, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing immunomedicines for cancer and other immune-related diseases. The company’s work centers on identifying biological pathways, biomarkers, and immune-cell interactions within the tumor microenvironment to create therapies for patients whose cancers do not respond well to current treatments. Its current programs emphasize targeted approaches such as antibody-drug conjugates and other differentiated mechanisms of action designed to address difficult-to-treat tumors. NextCure also uses its FIND-IO discovery platform to help identify novel immune targets and support pipeline development. Headquartered in Beltsville, Maryland, NextCure plays a specialized role in the oncology and immunology markets by advancing experimental therapies intended to improve treatment options for patients with limited alternatives.
Website9000 Virginia Manor Road
Beltsville, MD, 20705
United States
The latest articles about NXTC.
Summary of Aug 12's posts. Generated by AI.
Summary of Jul 17's posts. Generated by AI.
No summary yet.
Summary of Aug 12's posts. Generated by AI.
Investors talking about NXTC also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.